Explore the words cloud of the BETASCREEN project. It provides you a very rough idea of what is the project "BETASCREEN" about.
The following table provides information about the project.
|Coordinator Country||Sweden [SE]|
|Total cost||149˙365 €|
|EC max contribution||149˙365 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2017-02-01 to 2018-07-31|
Take a look of project's partnership.
|1||KAROLINSKA INSTITUTET||SE (STOCKHOLM)||coordinator||149˙365.00|
Validation of an in vivo translational medicine approach for the treatment of diabetes and diabetes complications
To develop new drugs for treatment of diabetes, there is an immediate need for an in vivo approach allowing the assessment of β-cell function and survival in the living organism non-invasively, longitudinally and at single-cell resolution. We therefore transplant pancreatic islets into the anterior chamber of the eye (ACE) of mice for functional microscopic imaging. In the ACE islets become vascularized and innervated, and various aspects of β-cell function and survival can be readily imaged. Functional studies demonstrate that engrafted islets in the eye serve as representative reporters of endogenous islets in the pancreas of the same animal. We have extensively in vitro tested fluorescent biosensors that reflect key-events in β-cell function and survival. Following intraocular transplantation of human islets expressing biosensors in their β-cells into healthy or diabetic mice, they will allow non-invasive, longitudinal in vivo monitoring of 1) Ca2 handling, 2) functional β-cell mass, 3) apoptosis and 4) proliferation. Based on the in vitro tested biosensors, the major objective is to establish a robust pharma-industry in vivo platform for validating newly developed diabetes treatment lead-compounds in early drug development. This screening service shall be performed on a commercial basis. The milestone of this proposal, to be achieved within 18 months, is the validation of the in vivo platform for testing the effects of new potential diabetes medicines on human β-cell function and survival in normal and diabetic mice.
|year||authors and title||journal||last update|
Ingo B. Leibiger, Per-Olof Berggren
Intraocular inÂ vivo imaging of pancreatic islet cell physiology/pathology
published pages: 1002-1009, ISSN: 2212-8778, DOI: 10.1016/j.molmet.2017.03.014
|Molecular Metabolism 6/9||2019-06-12|
Meike Paschen, Tilo Moede, Ismael Valladolid-Acebes, Barbara Leibiger, Noah Moruzzi, Stefan Jacob, Concha F. GarcÃa-Prieto, Kerstin Brismar, Ingo B. Leibiger, Per-Olof Berggren
Diet-induced Î²-cell insulin resistance results in reversible loss of functional Î²-cell mass
published pages: fj.201800826R, ISSN: 0892-6638, DOI: 10.1096/fj.201800826R
|The FASEB Journal||2019-06-12|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BETASCREEN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BETASCREEN" are provided by the European Opendata Portal: CORDIS opendata.